Skip to content
The Kids Research Institute Australia logo
Donate

Search

A diagnostic test for scabies: IgE specificity for a recombinant allergen of Sarcoptes scabiei

Scabies infestations are difficult to diagnose clinically and current serologic tests have less than 50% accuracy...

CD4 allergen tetramers

The introduction of class II tetramers for identifying antigen-binding CD41 cells has lagged behind the use of class I tetramers because of difficulties...

Homology modeling and monoclonal antibody binding of the der f 7 dust mite allergen

The group 7 allergens are important allergenic specificities for mite-sensitive patients and may need to be incorporated into new diagnostic and therapeutic...

Structural and IgE binding analyses of recombinant Der p 2 expressed from the hosts Escherichia coli and Pichia pastoris

The house dust mite allergen Der p 2 is one of the most important indoor allergens associated with allergic disease.

House dust mite allergens in asthma and allergy

IgE antibodies in house dust mite (HDM) allergy follow a predictable pattern. Half are directed against two dominant allergens and the remainder largely against

Early aberrant antibody responses of aeroallergen sensitised people to subclinical bacterial infection

Early aberrant antibody responses, aeroallergen sensitised people, subclinical bacterial infection

Investigations into the role of ST2 in acute asthma in children

This study investigated the potential role of ST2 in children with acute asthma.

RSV prophylaxis use in high-risk infants in Western Australia, 2002-2013: a record linkage cohort study

The monoclonal antibody, palivizumab is licensed for use in high-risk infants to prevent severe illness caused by respiratory syncytial virus (RSV). The level of its use and compliance with current jurisdictional guidelines which were amended in 2010, is unknown.

Clinical Management of Staphylococcus aureus Bacteremia in Neonates, Children, and Adolescents

Staphylococcus aureus is a common cause of community and health care-associated bacteremia, with authors of recent studies estimating the incidence of S aureus bacteremia (SAB) in high-income countries between 8 and 26 per 100 000 children per year. Despite this, <300 children worldwide have ever been randomly assigned into clinical trials to assess the efficacy of treatment of SAB.

Impact of the COVID-19 Pandemic on Tuberculosis Control

Throughout history, pandemics of viral infections such as HIV, Ebola and Influenza have disrupted health care systems, including the prevention and control of endemic diseases. Such disruption has resulted in an increased burden of endemic diseases in post-pandemic periods.